Streetbeat News

Regulatory

PALI

Palisade Bio shares are trading higher following the announcement that the European Patent Office has granted a patent for their Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 12:33 pm

PALI

Palisade Bio has announced that the European Patent Office has issued a decision to grant a patent for 'Gut Microbiota Bioactivated PDE4 Inhibitor Precursors,' covering their PALI-2108 and PALI-1908 programs. This patent provides Composition of Matter coverage until beyond 2042. PALI-2108 is being developed for Ulcerative Colitis, and PALI-1908 for Crohn's Disease.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 12:32 pm

SXTP

60 Degrees Pharmaceuticals has signed clinical trial agreements with Yale University, Rhode Island Hospital, and Tufts Medical Center for a study on Tafenoquine for Babesiosis. Patient enrollment has begun, with interim results expected by September 2025. The market for ARAKODA® (tafenoquine) for babesiosis is approximately 400,000 patients in the U.S.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 12:30 pm

INSP

Inspire Medical Systems has announced that it has received CE Mark certification under the European Union's Medical Device Regulation (EU MDR 2017/745) for its Inspire Therapy. This certification ensures compliance with the new, more stringent regulatory requirements enacted by the European Parliament in 2017.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 12:03 pm

MSFT

The FTC has criticized Microsoft for increasing the prices of Xbox Game Pass and introducing a new 'degraded' standard tier. The FTC argues that these changes, along with reduced investments in product quality, indicate Microsoft's market power post-merger with Activision Blizzard.

Portfolio Pulse from Rounak Jain

July 19, 2024 | 12:02 pm

DARE

Daré Bioscience, Inc. (NASDAQ:DARE) has regained compliance with Nasdaq's minimum bid price rule, as its stock price has been $1.00 or greater for 10 consecutive trading sessions.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 12:02 pm

BABA

Alibaba Group Holding Ltd (NYSE:BABA) is facing multiple challenges, including the departure of a key AI expert, Zhou Chang, and potential new U.S. sanctions on advanced semiconductor technology. Despite these challenges, Alibaba reported a 7% year-on-year increase in consolidated revenue, beating analyst expectations.

Portfolio Pulse from Anusuya Lahiri

July 19, 2024 | 11:39 am

EADSY

Airbus SE has received Type Certification from the European Union Aviation Safety Agency (EASA) for its A321XLR aircraft equipped with CFM LEAP-1A engines. This certification allows the aircraft to enter service by the end of summer. The A321XLR offers significant fuel efficiency and cost benefits, with over 500 units already ordered.

Portfolio Pulse from Nabaparna Bhattacharya

July 19, 2024 | 11:32 am

LLY

NVO

Eli Lilly's weight loss drug Zepbound (Tirzepatide) has been approved by China's National Medical Products Administration for long-term weight management. This approval could impact Eli Lilly (LLY) positively in the short term. Novo Nordisk (NVO) also received approval for its weight loss drug Wegovy in June, but faces competition as the patent for semaglutide expires in 2026.

Portfolio Pulse from Vandana Singh

July 19, 2024 | 11:26 am

AUGX

Trading halt status for AUGX was updated at 7:25:00 AM ET. The news and resumption times have been provided.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 11:25 am